Back to Search
Start Over
Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
- Source :
-
Primary care diabetes [Prim Care Diabetes] 2016 Dec; Vol. 10 (6), pp. 425-433. Date of Electronic Publication: 2016 Jul 04. - Publication Year :
- 2016
-
Abstract
- Aims: To evaluate the real-world effectiveness of vildagliptin and vildagliptin/metformin, combined with patient engagement, on glycemic outcomes. Patient engagement included both clinicians' engaging patients through education and counseling; and patients' self-engagement through disease awareness, lifestyle changes, and medication adherence.<br />Methods: Prospective, observational, open-label, multi-center, pharmacoepidemiologic study of type 2 diabetes mellitus (T2DM) patients treated de novo with vildagliptin or vildagliptin/metformin. Data were collected at baseline (treatment initiation), 105±15d, and ≥145d.<br />Results: The evaluable sample included 896 mainly male (58%), overweight (mean±SD BMI=30.3±5.4kg/m <superscript>2</superscript> ), in later middle age (mean±SD age=64±11years) patients. Over the three visits, mean(±SD) HbA1c levels declined from 8.1%(±1.0) to 7.3%(±1.0) to 7.2%(±0.9); HbA1c control rates rose from 7% to 36% to 43%. Mean±SD FPG levels decreased from 170(±49) to 141(±41) to 139(±42)mg/dL; control rates increased from 12% to 39% to 43% (all p<0.0001). Weight decreased nominally by 2kg (p=0.0290) and BMI by 0.8kg/m <superscript>2</superscript> (p<0.0001). Modeling showed patient engagement activities by clinicians and by patients to be major determinants of glycemic outcomes. No unknown safety signals were detected.<br />Conclusions: Vildagliptin and vildagliptin/metformin are effective and safe oral agents in the management of T2DM, especially if part of a treatment program with active patient engagement by clinicians and empowered patients.<br /> (Copyright © 2016 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Adamantane administration & dosage
Adamantane adverse effects
Administration, Oral
Aged
Biomarkers blood
Blood Glucose metabolism
Counseling
Diabetes Mellitus, Type 2 blood
Diabetes Mellitus, Type 2 diagnosis
Diabetes Mellitus, Type 2 psychology
Dipeptidyl-Peptidase IV Inhibitors adverse effects
Drug Combinations
Female
Glycated Hemoglobin metabolism
Health Knowledge, Attitudes, Practice
Humans
Hypoglycemic Agents adverse effects
Male
Medication Adherence
Metformin adverse effects
Middle Aged
Nitriles adverse effects
Patient Education as Topic
Prospective Studies
Pyrrolidines adverse effects
Risk Reduction Behavior
Self Care
Tablets
Treatment Outcome
Vildagliptin
Adamantane analogs & derivatives
Blood Glucose drug effects
Diabetes Mellitus, Type 2 drug therapy
Dipeptidyl-Peptidase IV Inhibitors administration & dosage
Hypoglycemic Agents administration & dosage
Metformin administration & dosage
Nitriles administration & dosage
Patient Participation
Pyrrolidines administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1878-0210
- Volume :
- 10
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Primary care diabetes
- Publication Type :
- Academic Journal
- Accession number :
- 27388795
- Full Text :
- https://doi.org/10.1016/j.pcd.2016.05.008